Navigation Links
Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
Date:4/11/2013

SUNNYVALE, Calif., April 11, 2013 /PRNewswire/ -- Pharmacyclics, Inc. (Nasdaq: PCYC) announced today that the Phase III clinical trial (RESONATE™-2), a monotherapy trial using ibrutinib versus chlorambucil in elderly patients with newly diagnosed chronic lymphocytic leukemia / small lymphocyctic lymphoma (CLL/SLL) has enrolled its fifth patient. The enrollment of the fifth patient has subsequently triggered a fourth $50 million milestone payment obligation from Janssen Biotech, Inc., one of the Janssen Pharmaceutical Companies of Johnson & Johnson, worldwide collaborator on ibrutinib in oncology.

This trial is a randomized, multicenter, open-label Phase III study of ibrutinib (PCI-32765) as a monotherapy versus chlorambucil in patients 65 years or older with treatment-naïve CLL/SLL. The study design is in accord with a Special Protocol Assessment (SPA). The study is designed to demonstrate superiority of ibrutinib with the primary endpoint of progression-free survival (PFS); the comparator is single agent chlorambucil. This global study is planned to enroll 272 patients worldwide.

Further information about this trial can be found at www.clinicaltrials.gov:
NCT01722487 – "A Multicenter, Open-label, Phase 3 Study of the Bruton's Tyrosine Kinase Inhibitor PCI-32765 versus Chlorambucil in Patients 65 Years or Older With Treatment-naive Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (RESONATE™-2)."

About the Janssen Collaboration
As previously announced on December 8, 2011, Pharmacyclics entered into a worldwide collaboration with Janssen to develop and commercialize ibrutinib, a novel, oral, first-in-class Bruton's Tyrosine Kinase (BTK) inhibitor. Pharmacyclics received from Janssen an upfront payment totaling $150 million upon signing the contr
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
2. Pharmacyclics, Inc. Prices Public Offering of Common Stock
3. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
4. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
5. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
6. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
7. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
8. Pharmacyclics Announces Oral Presentations and Clinical Update of Ibrutinib (PCI-32765) at the 2012 Annual Meeting of the American Society of Clinical Oncology
9. New survey finds women who suffer from migraines want a better understanding of migraine triggers
10. First sales of DIFICLIR™ by Astellas Pharma Europe triggers 10 Million Euro Milestone Payment to Optimer Pharmaceuticals
11. Cardinal Health Foundation, The Ohio State University Launch Fourth Toolkit to Help Reduce Abuse of Prescription Drugs on College Campuses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... DIEGO , Dec. 23, 2014 ResMed (NYSE: ... significant patent infringement action against Chinese medical device manufacturer BMC ... (ITC) ruled today that BMC,s masks listed below infringe ResMed,s ... or selling these masks in the United States ... iVolve N2 nasal mask , Willow nasal pillows mask ...
(Date:12/24/2014)... , Dec. 23, 2014   Synageva ... a biopharmaceutical company developing therapeutic products for rare ... Agency (EMA) of the Marketing Authorization Application (MAA) ... recently granted the company,s request for accelerated assessment, ... regulatory review time.   The MAA, ...
(Date:12/24/2014)...  Lockton Dunning Benefits, the Dallas ... addition of Vice President Kim Foerster ... Consulting team, Excelsior Solutions. Foerster ... the position.  Most recently, she worked as the ... Pharmacy, where she has held various managerial positions ...
Breaking Medicine Technology:ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3Kim Foerster Joins Lockton Companies 2
... DIEGO, Aug. 3, 2011 Proacta Incorporated and ... the expansion of their Collaborative Research, Development and ... a hypoxia-activated pro-drug for the treatment of cancer. ... parties agreed to expand their existing collaboration to ...
... Buehler Motor, Inc. ( http://www.buehlermotor.com ), a global ... challenging mechatronic drive solutions, today announced a partnership with ... of its DC/BLDC motor and gearmotor lines. ... South American medical equipment market, and introduce a new ...
Cached Medicine Technology:Proacta Incorporated and Yakult Honsha Announce Expansion of Their Collaborative Research, Development and Commercialization Agreement 2Proacta Incorporated and Yakult Honsha Announce Expansion of Their Collaborative Research, Development and Commercialization Agreement 3Buehler Motor Establishes Sales Partner in Brazil 2Buehler Motor Establishes Sales Partner in Brazil 3
(Date:12/25/2014)... 26, 2014 The microscopy market ... 7.2% to reach $5,756.0 million by 2019. Optical ... market. The electron microscopes product segment is expected ... period. , Rising focus on nanotechnology, technological advancements, ... the microscopy market. , Get Full Copy of ...
(Date:12/25/2014)... Dallas, TX (PRWEB) December 26, 2014 ... and Market Analysis to 2023” focuses on the ... commercial opportunities in the colorectal cancer market. Stivarga ... treatment of colon or rectal cancer. Boehringer Ingelheim ... inhibitor, for the treatment of refractory CRC in ...
(Date:12/25/2014)... “Every three months the trends for evening ... dress will be one of the hottest styles in the ... Today, the company releases 26 A-line sweetheart evening dresses, and ... , “We are trying our best to help a ... designs. Along with affordable prices, we provide discounted delivery costs ...
(Date:12/25/2014)... December 25, 2014 The short film “Color ... created in honor of a true 9/11 hero, Welles Remy ... festivals including the 24 hours of Nuremberg International Short Film ... , Actress, screenwriter and director Luciana Lagana ... film together with her husband, Gregory Graham - ...
(Date:12/25/2014)... 2014 Helen Harris’ RP (Retinitis Pigmentosa) ... California after an 8 year battle with breast cancer. ... evening in her home in Woodland Hills California after ... , As the founder and volunteer ... pioneered and championed many of today's greatest breakthroughs in ...
Breaking Medicine News(10 mins):Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Nintedanib Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 4Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 2Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 3Health News:RP International founder, Helen Harris Dies on Christmas Eve Just Hours Before Her Holiday Television Broadcast to Raise Funds to Cure Blindness was Broadcasted Nationally 4
... technology developed at the University at Buffalo has killed ... including airborne spores, viruses and bacteria in independent tests ... A prototype produced by Buffalo BioBlower Technologies LLC, a ... of better than one part per million in an ...
... Removal of Toxic Mercury,from Vaccines, NIXA, Mo., ... (ACIP) recommended yesterday that flu shots be,administered annually ... age. ACIP,functioning under the Centers for Disease Control ... by parents of vaccine-injured,children for neglecting vaccine safety ...
... PAULO, Brazil, Feb. 28 Medial Saude S/A,(BOVESPA: MEDI3) (MEDIAL SAUDE) announces the ... Quarter 2007 Earnings Conference Call, When: Thursday, March ... , How: Live over the Internet -- ... address above., Conference call dial-in phone ...
... European Commission Director General for Enterprise & Industry Heinz Zourek ... of an EC budget of 624 million to ESA as ... (GSC). , This will be provided in two stages: 419 ... of the GSC programme. Segment 2 will be submitted for ...
... Allscripts-Led Initiative Works With Google Health to Enable ... Collaboration between ... Direct from the 2008,HIMSS Exhibition and Conference, ... information solutions that physicians,use to improve healthcare, announced ...
... North Carolina State University have found that humans and ... also share the same genetic basis for certain types ... of the way the genomes have evolved, getting cancer ... Jaime Modiano, V.M.D., Ph.D., University of Minnesota College of ...
Cached Medicine News:Health News:UB's bioblower closer to protecting soldiers from biological attack 2Health News:UB's bioblower closer to protecting soldiers from biological attack 3Health News:CDC Vaccine Committee Recommends More Shots for Children 2Health News:Space sentinels: New 'tools' in space to improve European environment and security policies 2Health News:Space sentinels: New 'tools' in space to improve European environment and security policies 3Health News:The National ePrescribing Patient Safety Initiative Collaborates With Google 2Health News:The National ePrescribing Patient Safety Initiative Collaborates With Google 3Health News:The National ePrescribing Patient Safety Initiative Collaborates With Google 4Health News:U of Minn researchers discover genetic cancer link between humans and dogs 2Health News:U of Minn researchers discover genetic cancer link between humans and dogs 3
Compact networked patient monitors for flexible care....
... heritage in patient monitoring, IntelliVue has highly ... menu; built-in clinical support tools such as ... arrhythmia analysis; and many other powerful features., ... operates on a networked platform that can ...
... vital sign monitor. , ,Adult, pediatric, and neonatal. ... in patient care., ,Standard Functions: ,ECG - Respiration ... Multi-gas Sensor (HAL, ENF, ISO, DES, SEV, N ... ECG - FiO 2 - 2-Invasive Pressures - ...
... Welch Allyn Atlas monitor is a low-cost, ... IV anesthesia procedures, and surgery. The large ... that are visible from across the room. ... how to operate the monitor in just ...
Medicine Products: